DEXCOM, INC. (DXCM) 

Down 43% In 1 Day To Achieve Our Decline Target

Our February 18, 2024 issue highlighted DXCM as
“A Sell Above $125″with a “Decline Target of $84.50”.

With DexCom growing then at 27%/year, we said:

“DXCM’s current valuation at 15.4x Price/Sales
and 135x Price/Earnings
is just too high to pay for 27% growth”.

On July 25, 2024, DexCom reported Q2 results
that exceeded analysts’ expectations.
But, DexCom cut its growth forecast by half to 13%/year,
which caused DXCM to drop 43% in 1 day

Sometimes it takes a while,
but eventually valuation metrics do matter.
Our system analysis approach
has enabled great results for our Subscribers.

* * *

See our record at https://billionairestocktrader.com/our-record/
Listen to our podcasts at https://billionairestocktrader.com/podcasts/
Read & Listen to Sample Issue & Podcast
at https://billionairestocktrader.com/sample-issue/
Subscribe at https://billionairestocktrader.com/subscribe/ 

* * *

The information herein is provided solely to inform
and is not intended as, and is not to be construed as,
investment advice or as an investment recommendation.
Readers are advised to make their own investment decisions
and accept all responsibility thereof.
There is always risk of loss in publicly-traded stock trading & investing.
Past performance is not necessarily indicative of future results.